Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

University of Michigan

Technische Universitaet Muenchen

Technische Universitat Munchen

Amnon Hoffman

Chaim Gilon

Michael M Friedman

Joseph Holoshitz

Song Ling

Xiujun Pi

Eran Lavy

Adi Klinger

Denise De Almeida

Abraham Domb

Eli Breuer

Gabriel Nussbaum

Reuven Reich

Florian Rechenmacher

Ifat Katzhendler

Joseph Fanous

Horst Otto Kessler

Irina Cherniakov

Anna Elgart

Michael Weinmuller

Johnny Naoum

Eytan Klausner

Veerendhar Ainelly

Julia Frant

Dvora Izgelov

Abraham J Domb

Michael Weinmueller

Elgart Anna

Provided is a formulation and method for increasing bioavailability of an orally administered drug.

Formulation and method for increasing oral bioavailability of drugs

The present invention provides N-methylated cyclic hexapeptides comprising RGD and at least one alanine residue. The present invention further provides prodrugs comprising the cyclic hexapeptides. Pharmaceutical compositions comprising said cyclic hexapeptides are also disclosed as well as methods of their production and use in treating integrin related conditions and diseases.

N-methylated cyclic peptides and their prodrugs

The present invention provides prodrugs of somatostatin peptide and peptide analogs that are tissue permeable and oral bioavailable and enable activity of the somatostatin analog at the circulation or target tissue after cleavage of charge-masking lipophilic moieties. Pharmaceutical compositions comprising these prodrugs and their use in therapy and diagnosis are also provided.

Somatostatin prodrugs

A composition which comprises a biologically active agent and a polymer that exhibits a reverse thermal gelation at a physiological temperature, in a carrier, and in which the active agent is in an undissolved form is disclosed herein. Further disclosed herein are methods utilizing the compositions for treating subjects, including non-human subjects, as well as kits for preparing and using a composition. The composition is preferably a sustained release formulation, and is particularly useful for treating animals, where single-dose treatment is desired.

Sustained-release injectable formulation

Provided are backbone cyclized peptides that interfere with signaling of the intracellular adaptor protein MyD88. Pharmaceutical compositions including these backbone cyclized peptides as well as their use in treatment of multiple sclerosis (MS) and other diseases associated with MyD88 signaling are also disclosed.

Backbone cyclized inhibitory peptides of myeloid differentiation factor 88 (MyD88)

The present invention relates to methods and compositions for treating disease related to disorders of bone remodeling. In particular, the present invention relates to compositions and methods for treating rheumatoid arthritis.

Methods and compositions for the treatment of bone remodeling disorders

The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Compositions and methods for inducing an immune response

The present invention relates to novel metalloproteinase inhibitors having an aryloxybenzenesulfonamide moiety and a carbamoylphosphonic acid moiety, to pharmaceutical compositions comprising them, and to their uses in the prevention and/or treatment of disease or disorder associated with MMP.

Carbamoylphosphonates as inhibitors and uses thereof

Pharmaceutical gastroretentive drug delivery systems for the controlled release of an active agent in the gastrointestinal tract are disclosed, which comprise: (a) a single- or multi-layered matrix comprising a polymer that does not retain in the stomach more than a conventional dosage form selected from (1) degradable polymers that may be hydrophilic polymers not instantly soluble in gastric fluids, enteric polymers substantially insoluble at pH less than 5.5 and/or hydrophobic polymers and mixtures thereof; (2) non-degradable polymers; and any mixtures of (1) and (2); (b) a continuous or non-continuous membrane comprising at least one polymer having a substantial mechanical strength; and (c) a drug; wherein the matrix when affixed or attached to the membrane prevents evacuation from the stomach of the delivery system for a period of time of from about 3 to about 24 hours.

Gastroretentive controlled release pharmaceutical dosage forms

The present invention relates to a pharmaceutical controlled-release oral drug delivery system comprising as active ingredient at least one &bgr;-lactam antibiotic agent, having a specific absorption site in the small intestine in combination with a polymeric matrix, optionally further containing additional pharmaceutically acceptable constituents, wherein at least 50% of the &bgr;-lactam antibiotic agent are released from the matrix within from about 3 to about 4 hours from oral administration and the reminder of the pharmaceutical agent is released at a controlled rate. The drug delivery system according to the invention optionally further comprises a &bgr;-lactamase inhibitor, preferably in combination with amoxicillin and/or amoxicillin trihydrate as the active ingredient. The polymeric matrix of the pharmaceutical controlled-release oral drug delivery system of the invention my be of hydrophilic and/or hydrophobic nature and the delivery system may further comprise pharmaceutically acceptable additive. The pharmaceutical controlled-release oral drug delivery system of the invention is preferably in dosage unit form.

Pharmaceutical preparations for the controlled release of beta-lactam antibiotics

Growing community of inventors

Jerusalem, Israel

Amnon Hoffman